Trial purpose
Cancer treatment
Tumor type
Haematological
Age
18+
Clinical summary
Summary
All participants will receive subcutaneous injections of guadecitabine for the first 5 days of a 28 day treatment cycle. Treatments will be given for at least 6 of these 28 day cycles. This is a safety and efficacy trial, so any adverse events will be recorded and the effect of the study treatment on the lymphoma will be monitored using a PET or CT scan. This study will provide information about this study drug and allow subsequent study of this potential treatment for T-cell non-Hodgkin lymphoma.
Conditions
This trial is treating people with T-Cell Lymphoma
Eligibility
Inclusion
1) Age >18 years old
2) ECOG performance status 0-3.
3) Histologically confirmed diagnosis of a mature T-cell neoplasm, as defined by the 2016 World Health Organisation (WHO) classification system and including (but not restricted to):
a) Anaplastic large cell lymphoma (ALCL), ALK positive or negative
b) Angioimmunoblastic T-cell lymphoma (AITL)
c) Cutaneous T-cell lymphomas (CTCL) including mycosis fungoides (MF) and Sezary syndrome (SS).
d) Enteropathy associated T-cell lymphoma (EATL)
e) Hepatosplenic T-cell lymphoma (HSTL)
f) Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
g) T-cell prolymphocytic leukaemia (T-PLL)
4) Measurable disease as defined by disease presentation utilising standard response criteria for systemic (Cheson et al, Blood 2014) or cutaneous disease (Olsen et al, J Clin Oncol 2011).
5) Either:
a) Subjects with relapsed or refractory disease who are unsuitable for high-dose therapy and/or autologous stem cell transplantation in the opinion of the investigator.
b) Subjects with relapsed or refractory disease despite high-dose therapy and/or prior stem cell transplantation.
c) Subjects with newly diagnosed and previously untreated disease who are unfit to receive CHOP/CHOP-like therapy or the disease specific standard of care in the opinion of the investigator.
6) An interval of at least two weeks since treatment with chemotherapy, immunotherapy or biological therapy prior to enrolment. Corticosteroids up to 20mg per prednisolone equivalent per day are permitted for non-lymphoma indications and autoimmune manifestations of lymphoma (e.g. haemolysis).
7) Life expectancy > 3 months.
Exclusion
1) Prior treatment with guadecitabine or other DNA hypomethylating agent (e.g. azacitidine, decitabine).
2) Hypersensitivity to guadecitabine , azacitidine, decitabine or their excipients.
3) Second malignancy currently requiring active therapy except:
a. Breast or prostate cancer stable on or responding to endocrine therapy.
b. Pre-existing or concurrently diagnosed MDS (including chronic myelomonocytic leukaemia), or AML with bone marrow blasts <31%.
c. Non-melanomatous skin cancers such as basal or squamous cell carcinomas.
4) Patients with known active central nervous system involvement.
5) Renal impairment with creatinine clearance (as estimated by the Cockroft-Gault or other medically acceptable formula) <30ml/min.
6) Liver cirrhosis / chronic liver disease Child-Pugh B or C; total serum bilirubin >2.5x upper limit of normal (ULN), except for subjects with Gilbert’s syndrome for whom the direct bilirubin is <2.5 ULN.
7) Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection not controlled on antiviral therapy. Inactive hepatitis carrier status or low viral hepatitis titre on antivirals is permitted.
8) Inability to understand and comply with study procedures, or unable to provide written informed consent before any study-specific procedure.
9) Refractory congestive heart failure unresponsive to medical treatment; active infection resistant to all antibiotics; or advanced pulmonary disease requiring >2 litres per minute (LPM) oxygen.
10) Known illness or condition that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol.
11) Any uncontrolled intercurrent medical condition or laboratory abnormality, which would in the opinion of the investigator make participation unsafe.
12) Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures during the study and for at least 3 months after completing treatment and must agree not to become pregnant or father a child while receiving treatment with guadecitabine and for at least 3 months after completing treatment.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:
Trial sponsor
Astex Pharmaceuticals
Scientific Title
A phase 2, open label trial to evaluate safety, tolerability and efficacy of guadecitabine (SGI-110) in patients with T-cell lymphoma
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information